

Literatures:

*1 :Role of β2-microglobulin in uremic patients may be greater than originally suspected[J]. World Journal of Nephrology, 2015, 4(1): 98-104. doi: 10.5527/wjn.v4.i1.98.

*2 : González-Parra, Emilio, et al. "Bisphenol A in Chronic Kidney Disease." International Journal of Nephrology, vol. 2013, 2013, Article 437857, https://doi.org/10.1155/2013/437857

Corporate Headquarter

SHANDONG WEIGAO BLOOD PURIFICATION PRODUCTS CO., LTD.

International Business Headquarter

WEGO HEALTHCARE (SHENZHEN) CO., LTD.

19F, Building 3, Sunmax Technology Plaza, No.8 Keyuan Road,
Nanshan District, Shenzhen, China
Tel: +86 755 33892500 Fax:+86 755 33892508
E-mail: info@wego-healthcare.com
www.wego-healthcare.com/en

Solisent™

Broaden new horizons of high-quality dialysis.

Solisent™ High Flux Series

Safer Efficient Greener

WEGO
THE BLOOD PURIFICATION EXPERT

Comprehensively improved membrane biocompatibility

When hemodialysis initiates, blood and dialysis membrane come into contact, the dialysis membrane will inevitably adsorb plasma proteins, white blood cells, platelets, etc. The decrease of blood leukocytes generally occurs 1-2 minutes after dialysis initiation, reaches the lowest value at 15 minutes, and will return to the initial level after dialysis termination. The leukocytes reduction rate is usually be used as an indicator to evaluate the biocompatibility of dialysis membranes.

Leukocytes reduction rate at 15 minutes after dialysis initiation

Solisent™ HF series	Control group
-15.31±11.32%	-14.44±9.72%

* A randomized, parallel positive-controlled, non-inferiority trial was conducted. A total of 211 subjects were included and randomly divided into a test group (Solisent™ HF series) and a control group (F company) in a 1:1 ratio.

> Clinical data shows that during dialysis treatment, there is no significant difference in the effects of Solisent™ HF series and control group (F company FX series) on blood leukocytes.

Better removal of β2-MG

Higher blood β2-microglobulin(β2-MG) levels are associated with various cardiovascular risk factors, as well as all-cause mortality and cardiovascular mortality. Clinical studies suggest that β2-MG is an independent, significant predictor of mortality. *1

WEGO fourth-generation nano-spinning technology has optimized the pore size and porosity of the hollow fibers, enhancing the clearance of middle and large molecules, especially β2-MG. Clinical trials have shown that the β2-MG clearance rate of WEGO HF180 is 8.7% higher than that of E18H on average, effectively reducing the risk of dialysis-related amyloidosis and mortality, improving long-term outcomes, and extending patient survival time.





A randomized, parallel positive-controlled, non-inferiority clinical trial was conducted to evaluate the performance of the experimental group (HF180) with 106 cases, compared to the control group (E18H) with 108 cases.



All data taken from the manufacturer's user manual.

The high ultrafiltration coefficient enables a higher convection volume, improving endotoxin removal efficiency.



All data taken from the manufacturer's user manual.



When the blood flow rate was set at 200mL/min, there was no significant difference in the clearance rates of the four substances between HF180 and control group(F company FX CorDiax series);

When the blood flow rate was set at 300 and 400 mL/min, the clearance rates of urea, creatinine and phosphate of HF180 were significantly better than control group(F company FX CorDiax series).

* All data comes from laboratory tests.

Unique housing design

Optimized end-cap chamber design.

Avoid the formation of dead space in the end-cap, reduce the risk of blood coagulation, and ensure smooth blood flow during treatment;
The full-circle dialysate guide plate design can uniformize the dialysate flow, resulting in better endotoxin removal.

Ultrasonic welded housing.

The double-line ultrasonic welding structure is adopted to effectively avoid weld cracking and shell damage caused by external force, thereby improving product reliability.

BPA-free housing material.

Using BPA-free housing materials, ensuring safer long-term dialysis treatment *2.
WEGO Solisent™ dialyzers reduce CO_2 emissions by 8% compared to previous PC housing dialyzers of the same surface area, supporting the vision of green dialysis.





WEGO 4th generation spinning process

WEGO fourth-generation NIPS nanopore spinning technology has independent intellectual property rights. The three-layer asymmetric sponge-like membrane structure has a larger pore size and porosity on the inner surface, which can better remove medium and large molecular toxins; Medial compact layer can effectively entrap harmful substances such as endotoxins to ensure dialysis safety.







Profile of hollow fiber membrane wall | Hollow fiber membrane cross-section view | Hollow fiber membrane surface